The 23-gene diagnostic panel called myPath Melanoma could be used in addition to microscopy to distinguish the benign form of the disease from malignant disease.
A new 23-gene signature test (
, Myriad Genetics) could be helpful in these instances, researchers working with the company suggest.
The test was developed with a training set and then validated in an independent cohort. The results were
March 2 in the
Differentiating between malignant melanoma and benign skin moles can be difficult in about 15% of cases, where histopathologic analysis is not straightforward because of ambiguous findings. myPath Melanomapublished online Journal of Cutaneous Pathology
"myPath Melanoma is a powerful new molecular diagnostic test that analyzes genetic information inside skin cells to help us understand the biology of a patient's skin lesion and objectively differentiate benign moles from potentially lethal melanomas," researcher Loren Clarke, MD, medical director for dermatology at Myriad, said in a company press release.
"It is a tool for a pathologist to be used as an adjunct to microscopy," he told
Link to the article on Medscape:
Medscape Medical News